一分钟看懂
这是一项关于淋巴瘤的I 期 / II 期研究，登记的药物或干预包括CD5 CAR-T cells infusion，当前状态为招募中。登记地点显示中国北京、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
CD5 CAR-T cells infusion · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing GoBroad Hospital · 北京
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · 上海
- Shanghai Liquan Hospital · 上海
公开的入选条件
- (Patients who met all the inclusion criteria were eligible for enrolment):
- * Relapsed or refractory CD7-positive T-cell lymphomas that were treated with with standard chemotherapy, with poor prognosis from currently available treatments at and no available treatment options (e.g., HSCT or chemotherapy);
- * Male or female, age 14-70;
- * Eastern Cooperative Oncology Group (ECOG) Physical Status Score 0-2;
- * life expectancy is at least 60 days;
- * Subjects should be capable of understanding and signing the informed consent form prior to any screening procedures. Subjects are willing to follow the study visit schedule and associated study procedures as specified in the protocol. Candidates between the
- Exclusion Criteria (Patients who fulfil any of the following criteria may not be enrolled):
- * Patients with history of allogeneic HSCT but PBMNC is not available from prior- transplant donor for preparation of CAR T cells and peripheral blood tumour load \>30%; patients without history of allogeneic HSCT and peripheral blood tumour load \>30%;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07022964；登记信息更新于 2026-09-11。